Akari Therapeutics Plc

Akari Therapeutics Plc (AKTX)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

시가총액

$20K

수익

$0

P/E 비율

N/A

주가순자산비율

0.00

부채자본비율

0.15

배당 수익률

0.00%

마지막 업데이트: June 7 at 24:02:05